Icosavax (Icosavax) Retained Earnings : $-258.93 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Icosavax Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Icosavax's retained earnings for the quarter that ended in Sep. 2023 was $-258.93 Mil.

Icosavax's quarterly retained earnings declined from Mar. 2023 ($-210.39 Mil) to Jun. 2023 ($-236.89 Mil) and declined from Jun. 2023 ($-236.89 Mil) to Sep. 2023 ($-258.93 Mil).

Icosavax's annual retained earnings declined from Dec. 2020 ($-27.10 Mil) to Dec. 2021 ($-94.07 Mil) and declined from Dec. 2021 ($-94.07 Mil) to Dec. 2022 ($-185.83 Mil).

Icosavax Retained Earnings Historical Data

The historical data trend for Icosavax's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Retained Earnings Chart

Icosavax Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Retained Earnings

-8.24

-27.10

-94.07

-185.83

Icosavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Retained Earnings	Get a 7-Day Free Trial											-162.21	-185.83	-210.39	-236.89	-258.93

Icosavax Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Icosavax (NAS:ICVX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Icosavax (Icosavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101

Website

https://www.icosavax.com

Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Executives

Adam K. Simpson	director, officer: Chief Executive Officer	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan	officer: Chief Medical Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley	officer: Chief Business Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo	officer: Chief Financial Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman	officer: Chief Scientific Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan	officer: EVP, Head of Research & Dev.	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu	officer: See Remarks	1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson	officer: See Remarks	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil	director	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver	director	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p.	10 percent owner	GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807